Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores the pathogenesis, diagnosis, and treatment options for chronic autoimmune urticaria, highlighting the role of the oncostatin M receptor gene and reporting no new clinical results.

In this study, researchers did not find any genome-wide significant genetic signals linked to comorbid chronic inflammatory disorders in patients with alopecia areata, but exploratory analysis suggested potential associations worth further study.

This study introduces stem cell activity as a key factor influencing the effects of IFN-γ and TGF-β1 on autoimmune disease dynamics, showing that varying cytokine levels can modulate stem cell activity and immune privilege, impacting tissue regeneration and disease flares.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This review discusses the role of JAK inhibitors in treating atopic dermatitis, alopecia areata, and vitiligo, highlighting their effectiveness and safety considerations but stressing the need for further research on long-term safety and patient selection.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

This review discusses the potential of secretome derived from stem cells for treating alopecia areata and reports no new clinical results; the authors suggest the need for further human trials.

This study examined dermatological conditions in people with multiple sclerosis and found nevus and hair diseases to be the most common, indicating the importance of comprehensive skin examinations for early diagnosis and treatment.

This review discusses potential new drug treatment strategies for alopecia areata based on genome-wide association study findings, but it reports no new clinical results.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This case report highlights the onset of alopecia areata following dupilumab treatment, noting the significant temporal link between the medication use and hair loss occurrence.

This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This review discusses the mechanisms underlying the collapse of hair follicle immune privilege in alopecia areata and emphasizes the importance of therapeutic strategies aimed at restoring immune tolerance.

This review highlights the crucial role of the immune system in hair follicle regulation and its potential link to autoimmune disorders like alopecia areata. It suggests that understanding immune-mediated hair regeneration could lead to new treatments for this condition.

This study suggests that statins may help treat acute alopecia areata, with animal experiments showing increased regulatory T cell populations after statin treatment in mice with the condition.

This review discusses the pathogenesis and challenges in treating primary cicatricial alopecia, highlighting the need to understand immune protection collapse in hair follicle stem cells; it reports no new clinical results.

This review examines apoptotic and anti-apoptotic mechanisms in skin homeostasis and related diseases but presents no new research findings.

This review summarizes recent progress in microneedle-based drug delivery systems and discusses their potential impact on cellular mechanisms and immunization signaling pathways, highlighting the need for further development in fabrication methods.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study found that deleting Stim1 and Stim2 in mature T regulatory cells disrupts Ca 2+ signaling, preventing their differentiation and leading to severe autoimmune disorders in mice.

Regulatory T cells help prevent autoimmunity and have potential for treating autoimmune diseases.

This review discusses the current state of alopecia areata treatments, noting that while recent advances such as Janus Kinase inhibitors show promise, persistent challenges like limited efficacy, safety concerns, and patient compliance highlight the need for innovative drug discovery and development strategies.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

This study found that patients with alopecia areata in Dubai experience significant disease and economic burdens, especially when comorbid with psychological conditions, despite frequent dermatologist consultations and topical steroid prescriptions.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.